167 related articles for article (PubMed ID: 32667058)
41. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
42. The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex.
Chen L; Li G; Peng F; Jie X; Dongye G; Cai K; Feng R; Li B; Zeng Q; Lun K; Chen J; Xu B
Oncotarget; 2016 Dec; 7(49):80716-80734. PubMed ID: 27811372
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological and genetic evaluation of proposed roles of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and p90(RSK) in the control of mTORC1 protein signaling by phorbol esters.
Fonseca BD; Alain T; Finestone LK; Huang BP; Rolfe M; Jiang T; Yao Z; Hernandez G; Bennett CF; Proud CG
J Biol Chem; 2011 Aug; 286(31):27111-22. PubMed ID: 21659537
[TBL] [Abstract][Full Text] [Related]
44. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
[TBL] [Abstract][Full Text] [Related]
45. Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3β-AP1/Snail and JNK-AP1 pathways.
Pan CH; Chen SY; Wang JY; Tsao SP; Huang HY; Wei-Chen Chiu P; Wu CH
Chem Biol Interact; 2020 Dec; 332():109304. PubMed ID: 33164868
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT.
Jin Y; Huynh DTN; Kang KW; Myung CS; Heo KS
BMB Rep; 2019 Dec; 52(12):706-711. PubMed ID: 31818359
[TBL] [Abstract][Full Text] [Related]
47. Id4 promotes cisplatin resistance in lung cancer through the p38 MAPK pathway.
Qi K; Li Y; Li X; Lei X; Wang B; Zhang L; Chu X
Anticancer Drugs; 2016 Nov; 27(10):970-8. PubMed ID: 27537399
[TBL] [Abstract][Full Text] [Related]
48. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit.
Chae HD; Dutta R; Tiu B; Hoff FW; Accordi B; Serafin V; Youn M; Huang M; Sumarsono N; Davis KL; Lacayo NJ; Pigazzi M; Horton TM; Kornblau SM; Sakamoto KM
Oncotarget; 2020 Jun; 11(25):2387-2403. PubMed ID: 32637030
[TBL] [Abstract][Full Text] [Related]
49. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
50. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.
Roux PP; Richards SA; Blenis J
Mol Cell Biol; 2003 Jul; 23(14):4796-804. PubMed ID: 12832467
[TBL] [Abstract][Full Text] [Related]
51. [Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells].
Zhong H; Zuo Y; Wu X; Peng Y; He H; Yang J; Guan C; Xu Z
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):805-812. PubMed ID: 27978865
[TBL] [Abstract][Full Text] [Related]
52. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
53. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
[TBL] [Abstract][Full Text] [Related]
54. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
55. Molecular Targeting of ERKs/RSK2 Signaling in Cancers.
Cho YY
Curr Pharm Des; 2017 Nov; 23(29):4247-4258. PubMed ID: 28714417
[TBL] [Abstract][Full Text] [Related]
56. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways.
Wang Y; Qiu Q; Shen JJ; Li DD; Jiang XJ; Si SY; Shao RG; Wang Z
Int J Biochem Cell Biol; 2012 Nov; 44(11):1813-24. PubMed ID: 22750415
[TBL] [Abstract][Full Text] [Related]
57. Sox2 inhibits Wnt-β-catenin signaling and metastatic potency of cisplatin-resistant lung adenocarcinoma cells.
He J; Shi J; Zhang K; Xue J; Li J; Yang J; Chen J; Wei J; Ren H; Liu X
Mol Med Rep; 2017 Apr; 15(4):1693-1701. PubMed ID: 28259951
[TBL] [Abstract][Full Text] [Related]
58. Calotropin from Asclepias curasavica induces cell cycle arrest and apoptosis in cisplatin-resistant lung cancer cells.
Mo EP; Zhang RR; Xu J; Zhang H; Wang XX; Tan QT; Liu FL; Jiang RW; Cai SH
Biochem Biophys Res Commun; 2016 Sep; 478(2):710-5. PubMed ID: 27498029
[TBL] [Abstract][Full Text] [Related]
59. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
60. [The effects of Tumstatin185-191 on lung adenocarcinoma cell lines and the association with protein kinase B and extracellular regulated protein kinase activation].
Wang W; Chen P; Li JL; Pei YF; Shuang QC; Liu CH; Cai S; Liu SK; Zhu LY; Zhou R
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Feb; 33(2):123-7. PubMed ID: 20367953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
